The FDA approved Bristol Myers Squibb’s CAR‑T therapy Breyanzi for third‑line treatment of marginal zone lymphoma, making it the first CAR‑T cleared for that rare, indolent non‑Hodgkin lymphoma subtype. The approval expands Breyanzi’s label and provides a new option for patients with limited alternatives after multiple prior therapies. Bristol Myers cited clinical trial data supporting durable responses in heavily pretreated patients. The expansion underscores ongoing momentum for CAR‑T therapies beyond aggressive lymphomas into rarer indications and highlights the continued regulatory and commercial focus on cell therapies for hematologic malignancies. CAR‑T manufacturing and access remain operational bottlenecks; payers and providers will monitor uptake and real‑world durability post‑approval.